To the Editor: I read with interest the article by Dr Ross and colleagues1 on ghost authorship and guest authorship of original articles and reviews relating to rofecoxib that were presumably supported by Merck. I deplore the practice of ghost or guest authorship. I was dismayed, however, to note inclusion of a review2 that I coauthored in a table of articles that were implicitly tainted in this respect. A footnote indicates that the reason for inclusion was mention of one (or both) of the academic authors in Merck internal correspondence. The implication that the content of this article was in any way sponsored, influenced, previewed, or written by Merck is entirely incorrect.
FitzGerald GA. Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies. JAMA. 2008;300(8):900-906. doi:10.1001/jama.300.8.900-b